| Literature DB >> 28461567 |
Danish Saleh1,2, Malek Najjar3, Matija Zelic4, Saumil Shah5, Shoko Nogusa6, Apostolos Polykratis7,8,9, Michelle K Paczosa10, Peter J Gough11, John Bertin11, Michael Whalen12, Katherine A Fitzgerald13, Nikolai Slavov14, Manolis Pasparakis7,8,9, Siddharth Balachandran6, Michelle Kelliher4, Joan Mecsas15, Alexei Degterev16,2,3,5.
Abstract
The innate immune response is a central element of the initial defense against bacterial and viral pathogens. Macrophages are key innate immune cells that upon encountering pathogen-associated molecular patterns respond by producing cytokines, including IFN-β. In this study, we identify a novel role for RIPK1 and RIPK3, a pair of homologous serine/threonine kinases previously implicated in the regulation of necroptosis and pathologic tissue injury, in directing IFN-β production in macrophages. Using genetic and pharmacologic tools, we show that catalytic activity of RIPK1 directs IFN-β synthesis induced by LPS in mice. Additionally, we report that RIPK1 kinase-dependent IFN-β production may be elicited in an analogous fashion using LPS in bone marrow-derived macrophages upon inhibition of caspases. Notably, this regulation requires kinase activities of both RIPK1 and RIPK3, but not the necroptosis effector protein, MLKL. Mechanistically, we provide evidence that necrosome-like RIPK1 and RIPK3 aggregates facilitate canonical TRIF-dependent IFN-β production downstream of the LPS receptor TLR4. Intriguingly, we also show that RIPK1 and RIPK3 kinase-dependent synthesis of IFN-β is markedly induced by avirulent strains of Gram-negative bacteria, Yersinia and Klebsiella, and less so by their wild-type counterparts. Overall, these observations identify unexpected roles for RIPK1 and RIPK3 kinases in the production of IFN-β during the host inflammatory responses to bacterial infection and suggest that the axis in which these kinases operate may represent a target for bacterial virulence factors.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28461567 PMCID: PMC5471631 DOI: 10.4049/jimmunol.1601717
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422